Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor …

Lutetium-177 (Lu-177) PSMA therapy (Pluvicto) is a new theranostic treatment that targets a specific molecule on the surface of prostate cancer cells, effectively killing the cancer cells …

2024年1月20日 · Mayo Clinic researchers found that lutetium-177 (177 Lu)-PSMA-617 prolonged radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic …

2021年6月23日 · Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand …

What is PLUVICTO ® (lutetium Lu 177 vipivotide tetraxetan)? PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific …

Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen …

2025年2月1日 · Lutetium Lu 177 dotatate injection is used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors of the different …

On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for …

2023年1月18日 · Lutetium-177 (Lu-177) is a medical isotope used in targeted radionuclide therapy for treating neuroendocrine tumours and prostate cancer. It is produced in NRG’s …

Lutetium Lu 177-dotatate is approved to treat: Gastroenteropancreatic neuroendocrine tumors. It is used in adults and children aged 12 years and older whose cancer is somatostatin receptor …